Abstract
ADAMTS4 (Aggrecanase-1) is an important enzyme, which belongs to ADAMTS family. Aggrecanase-1 is involved in aggrecan degradation of articular cartilage in osteoarthritis and rheumatoid arthritis. Overall variability of S1’ domain of ADAMTS4 has been the main selectivity determinant to design the unique inhibitors. 34 inhibitors from Binding database and literature were used to develop the pharmacophore model. The five featured pharmacophore model AHHRR had the best survival score of 3.493 and post-hoc score of 2.545, indicating that the model is highly reliable. The 3D-QSAR acquired had excellent r2 value of 0.99 and GH score of 0.839. The validated pharmacophore model was used for insilico screening of Asinex and ZINC database for finding the potential lead compounds. ZINC00987406 and ASN04459656 which pose high glide score i.e >7 Kcal/mol and H-bond and hydrophobic interactions in the S1‘loop residues of ADAMTS4 were subjected to Molecular Dynamics Simulation studies. Molecular dynamic simulation result indicates that the RMSD and RMSF of backbone atoms for the above complexes were within the limit of 2.0 A˚. These compounds can be potential candidates for osteoarthritis by inhibiting ADAMTS4.
Keywords: ADAMTS4, pharmacophore, enrichment studies, docking studies, 3D-QSAR, molecular dynamics.
Combinatorial Chemistry & High Throughput Screening
Title:Identification of Potent Virtual Leads Specific to S1’ Loop of ADAMTS4: Pharmacophore Modeling, 3D-QSAR, Molecular Docking and Dynamic Studies
Volume: 19 Issue: 3
Author(s): P. Rathi Suganya, Sukesh Kalva and Lilly M. Saleena
Affiliation:
Keywords: ADAMTS4, pharmacophore, enrichment studies, docking studies, 3D-QSAR, molecular dynamics.
Abstract: ADAMTS4 (Aggrecanase-1) is an important enzyme, which belongs to ADAMTS family. Aggrecanase-1 is involved in aggrecan degradation of articular cartilage in osteoarthritis and rheumatoid arthritis. Overall variability of S1’ domain of ADAMTS4 has been the main selectivity determinant to design the unique inhibitors. 34 inhibitors from Binding database and literature were used to develop the pharmacophore model. The five featured pharmacophore model AHHRR had the best survival score of 3.493 and post-hoc score of 2.545, indicating that the model is highly reliable. The 3D-QSAR acquired had excellent r2 value of 0.99 and GH score of 0.839. The validated pharmacophore model was used for insilico screening of Asinex and ZINC database for finding the potential lead compounds. ZINC00987406 and ASN04459656 which pose high glide score i.e >7 Kcal/mol and H-bond and hydrophobic interactions in the S1‘loop residues of ADAMTS4 were subjected to Molecular Dynamics Simulation studies. Molecular dynamic simulation result indicates that the RMSD and RMSF of backbone atoms for the above complexes were within the limit of 2.0 A˚. These compounds can be potential candidates for osteoarthritis by inhibiting ADAMTS4.
Export Options
About this article
Cite this article as:
Suganya Rathi P., Kalva Sukesh and Saleena M. Lilly, Identification of Potent Virtual Leads Specific to S1’ Loop of ADAMTS4: Pharmacophore Modeling, 3D-QSAR, Molecular Docking and Dynamic Studies, Combinatorial Chemistry & High Throughput Screening 2016; 19 (3) . https://dx.doi.org/10.2174/1386207319666160127111318
DOI https://dx.doi.org/10.2174/1386207319666160127111318 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Systematic Review of the Role of Microparticles in Systemic Sclerosis
Current Rheumatology Reviews Glucocorticoid Analogues: Potential Therapeutic Alternatives for Treating Inflammatory Muscle Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Immunogenicity and its Impact on Benefit/Risk Considerations in the Authorisation of Biopharmaceuticals
Current Drug Safety The Prevalence of Depression in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Current Alzheimer Research Biological Therapies of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Gadd45 Proteins as Critical Signal Transducers Linking NF-κB to MAPK Cascades
Current Cancer Drug Targets Mood Stabilizers, Oxidative Stress and Antioxidative Defense in Euthymia of Bipolar Disorder
CNS & Neurological Disorders - Drug Targets Role of Galectins in Allergic Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Th1/Th17 Cytokine Profile is Induced by Macrophage Migration Inhibitory Factor in Peripheral Blood Mononuclear Cells from Rheumatoid Arthritis Patients
Current Molecular Medicine Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design Rheumatoid Arthritis Patients with Sjogrens Syndrome are More Prone to Depression than Patients with Rheumatoid Arthritis or Sjogrens Syndrome Alone
Current Rheumatology Reviews Systemic Lupus Erythematosus-Related Interstitial Lung Disease
Current Rheumatology Reviews Editorial (Thematic Issue: Anti-inflammatory Drugs in the Treatment of Inflammatory Periodontal Diseases)
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Chloroquine: An Old Drug with New Perspective Against Giardiasis
Recent Patents on Anti-Infective Drug Discovery Metabolism of HDL and its Regulation
Current Medicinal Chemistry Regulatory T Cells as Targets for Immunotherapy of Autoimmunity and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Supercritical Fluid Particle Design for Poorly Water-soluble Drugs (Review)
Current Pharmaceutical Design Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery